JP2022512913A5 - - Google Patents

Info

Publication number
JP2022512913A5
JP2022512913A5 JP2021524022A JP2021524022A JP2022512913A5 JP 2022512913 A5 JP2022512913 A5 JP 2022512913A5 JP 2021524022 A JP2021524022 A JP 2021524022A JP 2021524022 A JP2021524022 A JP 2021524022A JP 2022512913 A5 JP2022512913 A5 JP 2022512913A5
Authority
JP
Japan
Prior art keywords
cells
population
approximately
depleted
optionally
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021524022A
Other languages
English (en)
Japanese (ja)
Other versions
JP7604366B2 (ja
JP2022512913A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/059946 external-priority patent/WO2020097132A1/en
Publication of JP2022512913A publication Critical patent/JP2022512913A/ja
Publication of JP2022512913A5 publication Critical patent/JP2022512913A5/ja
Application granted granted Critical
Publication of JP7604366B2 publication Critical patent/JP7604366B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021524022A 2018-11-06 2019-11-05 遺伝子操作されたt細胞を作製するための方法 Active JP7604366B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862756571P 2018-11-06 2018-11-06
US62/756,571 2018-11-06
US201962798457P 2019-01-29 2019-01-29
US62/798,457 2019-01-29
PCT/US2019/059946 WO2020097132A1 (en) 2018-11-06 2019-11-05 Process for producing genetically engineered t cells

Publications (3)

Publication Number Publication Date
JP2022512913A JP2022512913A (ja) 2022-02-07
JP2022512913A5 true JP2022512913A5 (enExample) 2022-11-14
JP7604366B2 JP7604366B2 (ja) 2024-12-23

Family

ID=69159989

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021524022A Active JP7604366B2 (ja) 2018-11-06 2019-11-05 遺伝子操作されたt細胞を作製するための方法

Country Status (13)

Country Link
US (1) US20210393691A1 (enExample)
EP (1) EP3877054B1 (enExample)
JP (1) JP7604366B2 (enExample)
KR (1) KR20210100624A (enExample)
CN (1) CN113272018A (enExample)
AU (1) AU2019374790A1 (enExample)
BR (1) BR112021008738A2 (enExample)
CA (1) CA3117720A1 (enExample)
ES (1) ES2968737T3 (enExample)
IL (1) IL282754A (enExample)
MX (1) MX2021005021A (enExample)
SG (1) SG11202104183RA (enExample)
WO (1) WO2020097132A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2022005145A (es) 2019-10-30 2022-06-29 Juno Therapeutics Gmbh Dispositivos de estimulación y/o selección celular y método de uso.
US20220412954A1 (en) 2019-11-05 2022-12-29 Juno Therapeutics, Inc. Methods of determining attributes of therapeutic t cell compositions
JP7669048B2 (ja) * 2020-01-13 2025-04-28 アスペン ニューロサイエンス インコーポレイテッド 神経細胞を分化させる方法ならびに関連する組成物および使用方法
US12241086B2 (en) * 2020-04-15 2025-03-04 Amgen Inc. Process for generating genetically engineered autologous T cells
US12378521B2 (en) 2020-04-15 2025-08-05 Amgen Inc. Method for enhancing production of genetically engineered autologous T cells
KR20230022868A (ko) * 2020-05-13 2023-02-16 주노 쎄러퓨티크스 인코퍼레이티드 재조합 수용체를 발현하는 공여자-배치 세포의 제조 방법
CN117916256A (zh) 2021-05-06 2024-04-19 朱诺治疗学有限公司 用于刺激和转导t细胞的方法
CN114507274B (zh) * 2022-02-14 2023-08-25 西南大学 可逆结合生物素的链霉亲和素突变蛋白及其应用
CN117659145B (zh) * 2022-02-14 2024-08-02 西南大学 链霉亲和素第27位丝氨酸突变的突变蛋白s27v及其应用
US20230407252A1 (en) * 2022-04-28 2023-12-21 Allogene Therapeutics, Inc. Methods for donor cell analysis
WO2024100604A1 (en) * 2022-11-09 2024-05-16 Juno Therapeutics Gmbh Methods for manufacturing engineered immune cells
US20260232729A1 (en) * 2023-02-03 2026-08-13 C3S2 Gmbh Methods for non-viral manufacturing of engineered immune cells
CN116640192B (zh) * 2023-04-12 2024-08-02 西南大学 链霉亲和素突变体StrepTactin的Y43A突变蛋白及其应用
CN116785415B (zh) * 2023-05-04 2024-03-22 北京百普赛斯生物科技股份有限公司 一种特异性针对免疫细胞激活/增殖刺激的产品、制备及应用

Family Cites Families (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4361549A (en) 1979-04-26 1982-11-30 Ortho Pharmaceutical Corporation Complement-fixing monoclonal antibody to human T cells, and methods of preparing same
US4452773A (en) 1982-04-05 1984-06-05 Canadian Patents And Development Limited Magnetic iron-dextran microspheres
JP2624470B2 (ja) 1984-10-02 1997-06-25 バイオジェン インコーポレイテッド ストレプトアビジン様ポリペプチドの製造
US4690915A (en) 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
US4795698A (en) 1985-10-04 1989-01-03 Immunicon Corporation Magnetic-polymer particles
IN165717B (enExample) 1986-08-07 1989-12-23 Battelle Memorial Institute
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
US6303121B1 (en) 1992-07-30 2001-10-16 Advanced Research And Technology Method of using human receptor protein 4-1BB
ATE114507T1 (de) 1988-12-28 1994-12-15 Stefan Miltenyi Verfahren sowie materialien zur hochgraduierten magnetischen abspaltung biologischer materialien.
US5200084A (en) 1990-09-26 1993-04-06 Immunicon Corporation Apparatus and methods for magnetic separation
ATE159548T1 (de) 1990-11-13 1997-11-15 Immunex Corp Bifunktionelle wählbare fusionsgene
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
DE4228458A1 (de) 1992-08-27 1994-06-01 Beiersdorf Ag Multicistronische Expressionseinheiten und deren Verwendung
DE4237113B4 (de) 1992-11-03 2006-10-12 "Iba Gmbh" Peptide und deren Fusionsproteine, Expressionsvektor und Verfahren zur Herstellung eines Fusionsproteins
AU6953394A (en) 1993-05-21 1994-12-20 Targeted Genetics Corporation Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene
US5925517A (en) 1993-11-12 1999-07-20 The Public Health Research Institute Of The City Of New York, Inc. Detectably labeled dual conformation oligonucleotide probes, assays and kits
US5538848A (en) 1994-11-16 1996-07-23 Applied Biosystems Division, Perkin-Elmer Corp. Method for detecting nucleic acid amplification using self-quenching fluorescence probe
US5827642A (en) 1994-08-31 1998-10-27 Fred Hutchinson Cancer Research Center Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
WO1996013593A2 (en) 1994-10-26 1996-05-09 Procept, Inc. Soluble single chain t cell receptors
WO1996018105A1 (en) 1994-12-06 1996-06-13 The President And Fellows Of Harvard College Single chain t-cell receptor
WO1996024606A1 (en) 1995-02-09 1996-08-15 University Of Washington Modified-affinity streptavidin
WO1997011183A1 (en) 1995-04-11 1997-03-27 Trustees Of Boston University Streptavidin mutants
DE19608753C1 (de) 1996-03-06 1997-06-26 Medigene Gmbh Transduktionssystem und seine Verwendung
US6451995B1 (en) 1996-03-20 2002-09-17 Sloan-Kettering Institute For Cancer Research Single chain FV polynucleotide or peptide constructs of anti-ganglioside GD2 antibodies, cells expressing same and related methods
ATE186235T1 (de) 1996-04-24 1999-11-15 Claude Fell Zelltrennungsvorrichtung für biologische flüssigkeiten wie blut
SE506700C2 (sv) 1996-05-31 1998-02-02 Mikael Kubista Sond och förfaranden för analys av nukleinsyra
DE69739357D1 (de) 1996-06-04 2009-05-28 Univ Utah Res Found Überwachung der hybridisierung während pcr
DE19641876B4 (de) 1996-10-10 2011-09-29 Iba Gmbh Streptavidinmuteine
CA2283716A1 (en) 1997-03-14 1998-09-17 Gabriel O. Reznik Multiflavor streptavidin
CA2305630C (en) 1997-10-02 2012-11-06 Sunol Molecular Corporation Soluble single-chain t-cell receptor proteins
NZ507886A (en) 1998-05-19 2003-05-30 Avidex Ltd Multivalent T cell receptor complexes
WO1999061065A1 (en) 1998-05-23 1999-12-02 Leiden University Medical Center Cd40 binding molecules and ctl peptides for treating tumors
GB9812768D0 (en) 1998-06-13 1998-08-12 Zeneca Ltd Methods
WO2000014257A1 (en) 1998-09-04 2000-03-16 Sloan-Kettering Institute For Cancer Research Fusion receptors specific for prostate-specific membrane antigen and uses thereof
AU2472400A (en) 1998-10-20 2000-05-08 City Of Hope CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies
ES2224726T3 (es) 1998-12-24 2005-03-01 Biosafe S.A. Sistema de separacion sanguinea indicado en particular para la concentracion de celulas madre hematopoyeticas.
MXPA02007473A (es) 2000-02-01 2003-09-22 Tanox Inc Moleculas activadoras de celulas presentadoras de antigenos (apc) que se unen a cd40.
CA2410510A1 (en) 2000-06-02 2001-12-13 Memorial Sloan-Kettering Cancer Center Artificial antigen presenting cells and methods of use thereof
JP5213297B2 (ja) 2000-08-11 2013-06-19 ユニバーシティ オブ ユタ リサーチ ファウンデーション 単一ラベルオリゴヌクレオチド・プローブ
US7446179B2 (en) 2000-11-07 2008-11-04 City Of Hope CD19-specific chimeric T cell receptor
EP1227321A1 (en) 2000-12-28 2002-07-31 Institut für Bioanalytik GmbH Reversible MHC multimer staining for functional purification of antigen-specific T cells
DE10113776B4 (de) 2001-03-21 2012-08-09 "Iba Gmbh" Isoliertes streptavidinbindendes, kompetitiv eluierbares Peptid, dieses umfassendes Fusionspeptid, dafür codierende Nukleinsäure, Expressionsvektor, Verfahren zur Herstellung eines rekombinanten Fusionsproteins und Verfahren zum Nachweis und/oder zur Gewinnung des Fusionsproteins
US7070995B2 (en) 2001-04-11 2006-07-04 City Of Hope CE7-specific redirected immune cells
US20090257994A1 (en) 2001-04-30 2009-10-15 City Of Hope Chimeric immunoreceptor useful in treating human cancers
PT1421115E (pt) 2001-08-31 2005-07-29 Avidex Ltd Receptor de celulas t soluvel
US7939059B2 (en) 2001-12-10 2011-05-10 California Institute Of Technology Method for the generation of antigen-specific lymphocytes
US20030170238A1 (en) 2002-03-07 2003-09-11 Gruenberg Micheal L. Re-activated T-cells for adoptive immunotherapy
ITCZ20020002A1 (it) 2002-04-11 2003-10-13 Parco Scient E Tecnologico Del Dispositivo e metodo per il rilevamento simultaneo di differenti anticorpi e antigeni in campioni clinici, alimentari ed ambientali
US7446190B2 (en) 2002-05-28 2008-11-04 Sloan-Kettering Institute For Cancer Research Nucleic acids encoding chimeric T cell receptors
WO2007001459A2 (en) 2004-11-15 2007-01-04 Washington University Compositions and methods for modulating lymphocyte activity
FR2841905B1 (fr) 2002-07-05 2004-09-03 Centre Nat Rech Scient Fragments fab mutants de l'anticorps anti-cd4 chimere 13b8.2 et leurs applications
AU2003271904B2 (en) 2002-10-09 2009-03-05 Adaptimmune Limited Single chain recombinant T cell receptors
US20050129671A1 (en) 2003-03-11 2005-06-16 City Of Hope Mammalian antigen-presenting T cells and bi-specific T cells
EP1791865B1 (en) 2004-06-29 2010-07-28 Immunocore Ltd. Cells expressing a modified t cell receptor
EP1812465B1 (en) 2004-11-12 2016-09-07 Genentech, Inc. Novel composition and methods for the treatment of immune related diseases
CA2589279A1 (en) * 2004-11-24 2006-06-01 Val-Chum, S.E.C. Methods to identify, prepare, and use naive t cell recent thymic emigrants
US20080171951A1 (en) 2005-03-23 2008-07-17 Claude Fell Integrated System for Collecting, Processing and Transplanting Cell Subsets, Including Adult Stem Cells, for Regenerative Medicine
GB0620894D0 (en) 2006-10-20 2006-11-29 Univ Southampton Human immune therapies using a CD27 agonist alone or in combination with other immune modulators
US8389282B2 (en) 2007-03-30 2013-03-05 Memorial Sloan-Kettering Cancer Center Constitutive expression of costimulatory ligands on adoptively transferred T lymphocytes
BRPI0811466A2 (pt) 2007-05-07 2014-10-14 Medimmune Llc Anticorpo anti-icos isolado, ácido nucleico, vetor, célula isolada, métodos para produzir um anticorpo, para tratar uma doença ou distúrbio, para tratar ou prevenir a rejeição em um paciente de transplante humano, para tratar uma malignidade de célula t em um ser humano, para esgotar células t que expressam icos em um paciente humano, para romper a arquitetura do centro germinal em um órgão linfóide secundário de um primata, para esgotar células b centrais germinais de órgão linfóide secundário de um primata, e para esgotar células b comutadas em classes circulantes em um primata, e, composição farmacêutica.
EP2520643B8 (en) 2007-12-07 2019-11-27 Miltenyi Biotec B.V. & Co. KG Sample processing systems and methods
US8479118B2 (en) 2007-12-10 2013-07-02 Microsoft Corporation Switching search providers within a browser search box
US20120164718A1 (en) 2008-05-06 2012-06-28 Innovative Micro Technology Removable/disposable apparatus for MEMS particle sorting device
JP5173594B2 (ja) 2008-05-27 2013-04-03 キヤノン株式会社 管理装置、画像形成装置及びそれらの処理方法
CA2735456C (en) 2008-08-26 2021-11-16 City Of Hope Method and compositions for enhanced anti-tumor effector functioning of t cells
WO2011044186A1 (en) 2009-10-06 2011-04-14 The Board Of Trustees Of The University Of Illinois Human single-chain t cell receptors
JP5956342B2 (ja) 2009-11-03 2016-07-27 シティ・オブ・ホープCity of Hope 形質導入T細胞選択のためのトランケート上皮増殖因子レセプタ(EGFRt)
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
WO2012129514A1 (en) 2011-03-23 2012-09-27 Fred Hutchinson Cancer Research Center Method and compositions for cellular immunotherapy
US8398282B2 (en) 2011-05-12 2013-03-19 Delphi Technologies, Inc. Vehicle front lighting assembly and systems having a variable tint electrowetting element
ES2682750T5 (en) 2011-07-18 2025-02-04 Iba Lifesciences Gmbh Method of reversibly staining a target cell
GB201116092D0 (en) 2011-09-16 2011-11-02 Bioceros B V Antibodies and uses thereof
WO2013071154A1 (en) 2011-11-11 2013-05-16 Fred Hutchinson Cancer Research Center Cyclin a1-targeted t-cell immunotherapy for cancer
EP2814846B1 (en) 2012-02-13 2020-01-08 Seattle Children's Hospital d/b/a Seattle Children's Research Institute Bispecific chimeric antigen receptors and therapeutic uses thereof
WO2013126726A1 (en) 2012-02-22 2013-08-29 The Trustees Of The University Of Pennsylvania Double transgenic t cells comprising a car and a tcr and their methods of use
SG11201404991YA (en) 2012-02-23 2014-09-26 Stage Cell Therapeutics Gmbh Chromatographic isolation of cells and other complex biological materials
NZ702108A (en) 2012-05-03 2016-09-30 Hutchinson Fred Cancer Res Enhanced affinity t cell receptors and methods for making the same
LT2884999T (lt) 2012-08-20 2021-04-12 Fred Hutchinson Cancer Research Center Ląstelinės imunoterapijos būdas ir kompozicijos
RU2729401C2 (ru) 2012-10-02 2020-08-06 Мемориал Слоан-Кеттеринг Кэнсер Сентер Композиции и способы для иммунотерапии
EP2920204B1 (en) 2012-11-16 2019-09-18 IBA GmbH Streptavidin muteins and methods of using them
UY35468A (es) 2013-03-16 2014-10-31 Novartis Ag Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
IL292038B2 (en) 2014-04-23 2024-12-01 Juno Therapeutics Inc Methods for enriching or producing immune cell populations for adoptive therapy
EP3166968B1 (en) 2014-05-02 2021-09-22 The Trustees of the University of Pennsylvania Compositions and methods of chimeric autoantibody receptor t cells
TWI751102B (zh) 2014-08-28 2022-01-01 美商奇諾治療有限公司 對cd19具專一性之抗體及嵌合抗原受體
JP6740234B2 (ja) 2014-11-05 2020-08-12 ジュノー セラピューティクス インコーポレイテッド 形質導入および細胞プロセシングのための方法
CN108137669B (zh) * 2015-05-18 2023-02-17 优瑞科生物技术公司 抗ror1嵌合抗原受体
KR102427334B1 (ko) * 2016-04-01 2022-08-03 카이트 파마 인코포레이티드 키메라 항원 및 t 세포 수용체 및 사용 방법
CN110913690A (zh) 2017-03-14 2020-03-24 朱诺治疗学股份有限公司 用于低温储存的方法
AU2018260380B2 (en) 2017-04-27 2025-02-13 Juno Therapeutics Gmbh Oligomeric particle reagents and methods of use thereof

Similar Documents

Publication Publication Date Title
JP2021533746A5 (enExample)
JP7832892B2 (ja) Lilrb1ベースのキメラ抗原受容体
JP2020530294A5 (enExample)
CN106074601B (zh) 用于细胞免疫治疗的方法和组合物
CN109266667B (zh) 靶向cd5的嵌合抗原受体及其应用
JP2022531222A5 (enExample)
AU2017301880A1 (en) Immunomodulatory polypeptides and related compositions and methods
KR102316091B1 (ko) Bcma를 표적으로 하는 키메라 항원 수용체 및 이의 용도
HK1255208A1 (zh) 作为用於嵌合抗原受体(car)疗法的t细胞来源的骨髓浸润淋巴细胞(mil)
US12522644B2 (en) T cell receptors and methods of use thereof
KR20210100624A (ko) 유전적으로 조작된 t 세포를 제조하는 방법
JP2013176373A (ja) T細胞レセプターβ鎖遺伝子及びα鎖遺伝子
CN110511912A (zh) 免疫细胞的功能调节
WO2021030153A2 (en) Engineered t cell receptors and uses thereof
CN111826353B (zh) 调节t细胞功能和反应的方法
WO2021030182A1 (en) Bifunctional single variable domain t cell receptors and uses thereof
JP2025536940A (ja) 新規cd19バインダー、それを含むcar-t構造体、およびその使用方法
JP2016501268A (ja) 新規mhc非依存性腫瘍関連抗原
WO2023207390A1 (zh) 一种ciita基因被敲除的工程化免疫细胞及其用途
WO2025213573A1 (zh) 细胞免疫疗法的组合物和方法
CN116490518A (zh) 用于重定向免疫抑制信号传导的嵌合MyD88受体及相关组合物和方法
JP2024534499A (ja) Il5ra細胞表面マーカー
CA3225682A1 (en) Anti-egfrviii antibody, polypeptide, cell capable of expressing said polypeptide, pharmaceutical composition comprising said cell, method for producing said cell, and polynucleotide or vector comprising nucleotide sequence encoding said polypeptid
EP4372089A1 (en) Chimeric antigen receptor, cell capable of expressing said receptor, pharmaceutical composition containing said cell, method for producing said cell, and polynucleotide or vector which contains nucleotide sequence encoding said chimeric antigen receptor
RU2795454C2 (ru) Способы и композиции для получения генно-инженерных клеток